The COVID-19 pandemic changed the way of performing clinical therapeutic research. The platform trial REMAP-CAP proved to be highly efficient and provided evidence-based guidance for treatment of patients hospitalized with COVID-19. Platforms clearly represent the future of clinical trials. In this session the beauty, complexity and results from the REMAP-CAP trial will be presented, complemented by the description of yet another new platform trial for evaluating COVID-19 treatment in primary care.